Nephroprotective effects of GLP-1 receptor agonists: where do we stand?

por Mosterd, Charlotte M., Bjornstad, Petter, van Raalte, Daniël H.
Publicado 2020

Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized cros...

por Scholtes, Rosalie A., Mosterd, Charlotte M., Hesp, Anne C., Smits, Mark M., Heerspink, Hiddo J. L., van Raalte, Daniël H.
Publicado 2022

Inflammation and its associations with aortic stiffness, coronary artery disease and peripheral artery disease in different ethnic groups: The HELIUS Study

por Hayfron-Benjamin, Charles F., Mosterd, Charlotte, Maitland - van der Zee, Anke H., van Raalte, Daniel H., Amoah, Albert G.B., Agyemang, Charles, van den Born, Bert-Jan
Publicado 2021

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes

por van der Hoek, Sjoukje, Koomen, Jeroen V., van Bommel, Erik J. M., Mosterd, Charlotte M., Scholtes, Rosalie A., Hesp, Anne C., Stevens, Jasper, van Raalte, Daniel H., Heerspink, Hiddo J. L.
Publicado 2023